Product
Supplier
Encyclopedia
Inquiry
Home > Active Pharmaceutical Ingredients > Other Chemical Drugs > Tirzepatide for Sale > CAS 2023788-19-2 Weight Loss Peptide GLP-1 Tirzepatide, 99% Purity Raw materials
CAS 2023788-19-2 Weight Loss Peptide GLP-1 Tirzepatide, 99% Purity Raw materials buy - large image1
CAS 2023788-19-2 Weight Loss Peptide GLP-1 Tirzepatide, 99% Purity Raw materials buy - image1
CAS 2023788-19-2 Weight Loss Peptide GLP-1 Tirzepatide, 99% Purity Raw materials buy - image2
CAS 2023788-19-2 Weight Loss Peptide GLP-1 Tirzepatide, 99% Purity Raw materials buy - image3
CAS 2023788-19-2 Weight Loss Peptide GLP-1 Tirzepatide, 99% Purity Raw materials buy - image4
CAS 2023788-19-2 Weight Loss Peptide GLP-1 Tirzepatide, 99% Purity Raw materials buy - image5
CAS 2023788-19-2 Weight Loss Peptide GLP-1 Tirzepatide, 99% Purity Raw materials buy - image6

CAS 2023788-19-2 Weight Loss Peptide GLP-1 Tirzepatide, 99% Purity Raw materials

TDS 2101 Inquiries

Unit Price:

$65-75/UNIT FOB

Get Latest Price
CAS No.:

2023788-19-2

Grade:

Pharmaceutical Grade

Content:

99%

Port:

shenzhen

Brand:

KS

Packaging:

5mg,10mg,20mg,30mg,40mg,60mg/vial, 10vials/box

Sample Available:

Yes

Price valid (until):

2027-08-26

Company Type:
Trader
Location:
China
Payment Terms:
TT against copy of documents,L/C,TT against B/L draft before shipment,100% TT in advance
Average Lead Time:
1 days
Qualification:
Main Products:

GLP-1,semaglutide,Retatrutide,Tirzepatide

  • Product Details

  • Seller Information

  • Inquiry History

  • Description


    Sales Manager


    NAME: Nancy

    Whats App:+86 15226890287

    Email:nancy@xtkstech.cn

    Welcome to concult~


       Basic Message  


    Items Specifications
    Product name Tirzepatide
    CAS No. 2023788-19-2
    Appearance White powder
    Molecular weight
    4113.57754
    Purity ≥99%
    Function Fitness and Weight Loss
    Shop CAS 2023788-19-2 Weight Loss Peptide GLP-1 Tirzepatide, 99% Purity Raw materials-Detailed Image 1


      Product Detail   


    Tirzepatide (LY3298176) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor .

    This medication is designed to improve glycemic control in people with type 2 diabetes by targeting both the GIP and GLP-1 receptors. By stimulating these receptors, tirzepatide can increase insulin secretion and decrease glucagon secretion in a glucose-dependent manner, helping to lower blood sugar levels.

    Clinical trials have shown promising results in terms of reducing HbA1c levels and body weight in individuals with type 2 diabetes. Tirzepatide is being studied in various dosages and formulations to determine its effectiveness, safety, and potential benefits for people with diabetes

    NOTE: This product was prepared by chemical synthesis. Used only for research. 

    Shop CAS 2023788-19-2 Weight Loss Peptide GLP-1 Tirzepatide, 99% Purity Raw materials-Detailed Image 2

    Shop CAS 2023788-19-2 Weight Loss Peptide GLP-1 Tirzepatide, 99% Purity Raw materials-Detailed Image 3

    Shop CAS 2023788-19-2 Weight Loss Peptide GLP-1 Tirzepatide, 99% Purity Raw materials-Detailed Image 4

    Shop CAS 2023788-19-2 Weight Loss Peptide GLP-1 Tirzepatide, 99% Purity Raw materials-Detailed Image 5


       Product Fuction 


    1. The inhibitory effect  on glucagon

    Tirzepatide can inhibit the secretion of glucagon, thereby reducing the amount of glucose released by the liver and lowering blood sugar levels. This inhibitory effect on glucagon is one of the unique mechanisms of action of tiesipatid, which helps to lower the blood sugar peak in diabetic patients and control blood sugar in the long term.

    2. The weight management function 

    Tirzepatide has the effect of suppressing appetite and increasing a sense of fullness . Through the action of the central nervous system, the gastric emptying time is prolonged and the food intake is reduced, thereby achieving the goal of weight loss. This gives tiesipatide a unique advantage in the treatment of Tirzepatide. It can not only improve blood sugar control but also promote weight loss.

    3. The cardiovascular protective effect 

    People with diabetes have an increased risk of cardiovascular complications. Cardiovascular protection is an important goal in the treatment of diabetes. Tirzepatide can reduce the presence of cardiovascular risk factors through multiple pathways, such as improving blood sugar control, reducing weight, and enhancing lipid metabolism.

    Shop CAS 2023788-19-2 Weight Loss Peptide GLP-1 Tirzepatide, 99% Purity Raw materials-Detailed Image 6
    Shop CAS 2023788-19-2 Weight Loss Peptide GLP-1 Tirzepatide, 99% Purity Raw materials-Detailed Image 7 Shop CAS 2023788-19-2 Weight Loss Peptide GLP-1 Tirzepatide, 99% Purity Raw materials-Detailed Image 8


    Type of shipping


    Shop CAS 2023788-19-2 Weight Loss Peptide GLP-1 Tirzepatide, 99% Purity Raw materials-Detailed Image 9


      Payment Methods 


    Shop CAS 2023788-19-2 Weight Loss Peptide GLP-1 Tirzepatide, 99% Purity Raw materials-Detailed Image 10


       Our Factory   


    Hongbai Technology Co., Ltd. is  a branch of Changsha Dolo Technology Co., Ltd.,which is a pioneering force in the biotechnology sector.

    At the core of our operations is the unwavering commitment to our guiding principles : "Quality First, Service Supreme."Our mission is to spearhead advancements in biotechnology by consistently upholding the highest standards of quality and service. Through innovation and excellence, we aim to contribute to the betterment of global health and well-being.

    Our primary focus encompasses a range of products , including weight loss peptides, cosmetic peptides, and customized peptides. Notable among our weight loss peptide offerings are Tirzepatide, Retatrutide, and others.Provides reliable and timely custom manufacturing services for API following stringent quality system and close communication with the Clients.We have professional sales team , focus on quality and service, and we have achieved excellent performance over the years. Our company is committed to the development of international market, our products are mainly exported to many countries and regions, such as Europe, America, South-east Asia, the Middle East and Africa etc.

    With our constant efforts and good service, We sincerely hope to establish long-term cooperation and common development with our customers .

    Shop CAS 2023788-19-2 Weight Loss Peptide GLP-1 Tirzepatide, 99% Purity Raw materials-Detailed Image 11
    Shop CAS 2023788-19-2 Weight Loss Peptide GLP-1 Tirzepatide, 99% Purity Raw materials-Detailed Image 12

    Shop CAS 2023788-19-2 Weight Loss Peptide GLP-1 Tirzepatide, 99% Purity Raw materials-Detailed Image 13

    Shop CAS 2023788-19-2 Weight Loss Peptide GLP-1 Tirzepatide, 99% Purity Raw materials-Detailed Image 14
    ECHEMI Editorial Reference

    Tirzepatide (LY3298176) was developed as a dual agonist to both GLP-1 and gastric inhibitory polypeptide (GIP) receptors (Frias et al., 2018). Similar to GLP-1, GIP is an incretin hormone that functions to induce insulin secretion.

    Certificates
    • CAS 2023788-19-2 Weight Loss Peptide GLP-1 Tirzepatide, 99% Purity Raw materials Certificates 1 TDS

    Basic Info
    Product Name:

    Tirzepatide

    Other Name:

    LY3298176;

    CAS No.:

    2023788-19-2

    Molecular Formula:

    C225H348N48O68

    Molecular Weight:

    4813

    EC Number:

    200-001-8

    Categories:

    Other Chemical Drugs

    Characteristics
    Appearance:

    White to off-white

    Research
    Class:

    Dual agonist — GIPR, GLP-1R

    Status:

    FDA-approved (Mounjaro / Zepbound)

    Mechanism:

    Dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. A 39-amino-acid modified peptide with a C20 fatty diacid moiety that enables albumin binding for extended half-life (~5 days). Selectively activates both GIPR and GLP-1R signaling pathways.

    EC50 (Human GLP1R):

    0.934 nM

    EC50 (Human GIPR):

    0.0224 nM

    Source:

    Frias JP, et al. N Engl J Med. 2021;385(6):503-515.DOI

    FDA:

    Mounjaro, Zepbound (approved 2022-05-13)

    References
    ChEMBL:

    CHEMBL4297839

    DrugBank:

    DB15171

    KEGG DRUG:

    D11360

    PubChem:

    PubChem

    Disclaimer:

    Tirzepatide is approved as a prescription medicine (Mounjaro, Zepbound) in certain jurisdictions. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.

  • Seller Information
    Business Type:

    Trader

    Main Products:

    GLP-1,semaglutide,Retatrutide,Tirzepatide

    Location:

    Room 2012, No. 6-143, Section 2, Shanghai Road, Guta District, Jinzhou City, Liaoning Province

    Payment Terms:

    TT against copy of documents,L/C,TT against B/L draft before shipment,100% TT in advance

    Average lead Time:

    1 days

    Year of Establishment:

    2024

  • Inquiry History
    2101 Inquiries
    Country Product Purchase Quantity Date Posted
    Brazil

    Tirzepatide

    100 G Oct 28, 2026
    Belgium

    Tirzepatide

    10 MG Oct 28, 2026
    United States

    tirzepatide

    100 MG Oct 28, 2026
    United States

    Tirzepatide

    60 MG Oct 28, 2026
    United States

    Tirzepatide

    10 PCS Oct 28, 2026
    United States

    tirzepatide

    30 MG Oct 27, 2026
    United States

    Tirzepatide

    40 MG Oct 27, 2026
    Philippines

    Tirzepatide

    2 MT Oct 27, 2026
    Philippines

    Tirzepatide

    30 MG Oct 26, 2026
    Slovakia

    Tirzepatide

    1 G Oct 26, 2026
    France

    Tirzepatide

    1 KG Oct 25, 2026
    United States

    Tirzepatide

    2.5 MG Oct 25, 2026
    United Kingdom

    Tirzepatide

    5 MT Oct 25, 2026
    United Kingdom

    Tirzepatide

    6 MT Oct 24, 2026
    Peru

    tirzepatide

    10 MG Oct 21, 2026
    Puerto Rico

    tirzepatide

    40 MG Oct 21, 2026
    United States

    Tirzepatide

    10 MT Oct 21, 2026
    South Africa

    Tirzepatide

    1 MT Oct 20, 2026
    United States

    Tirzepatide

    5 KG Oct 20, 2026
    United States

    tirzepatide

    30 MG Oct 20, 2026
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.